A research team at the University of Osaka has unveiled the molecular mechanism behind genome ejection from adeno-associated virus (AAV) vectors, a crucial delivery vehicle in gene therapy.

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their research efforts around the adeno-associated virus (AAV) vectors used ...

In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form of epilepsy, scientists have developed a new gene replacement therapy ...

“People have a deficiency of a certain gene. We take that gene, we are able to put it into our cells, make it bigger, large amount of quantity to treat people,” explained Matica COO Brian Greven.

Danish start-up Fuse Vectors has received $5.2 million in preseed financing to further develop their gene therapy technology. The company has developed a cell-free platform for producing adeno ...

Today, Fuse Vectors announces $5.2 million in pre-seed financing led by HCVC to revolutionize gene therapy development with its cell-free viral vector technology. The funding will accelerate the ...

Copenhagen, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Gene therapy's biggest obstacle isn't science - it's manufacturing. While the field races forward with breakthrough treatments, production remains stuck ...

Today, Fuse Vectors announces $5.2 million in pre-seed financing led by HCVC to revolutionize gene therapy development with its cell-free viral vector technology .